JSETRI
DEAD

Serial Number

79335697

Owner

NOVARTIS AG

Attorney

Maury M. Tepper, III

Filing Date

Jan 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

JSETRI Trademark

Serial Number: 79335697 • Registration: 6791831

JSETRI is a trademark filed by NOVARTIS AG on January 25, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NOVARTIS AG (7,135 trademarks)

CH-4002
BASEL , CH

Entity Type: 03

Trademark Details

Filing Date

January 25, 2022

Registration Date

July 19, 2022

Published for Opposition

May 3, 2022

Cancellation Date

October 2, 2024

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 12, 2025 DENA
DEATH OF INTERNATIONAL REGISTRATION
Jun 12, 2025 DETH
NOTIFICATION PROCESSED BY IB
Sep 25, 2022 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Sep 6, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 6, 2022 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Aug 18, 2022 GPAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 19, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 19, 2022 R.PR
NOTIFICATION PROCESSED BY IB
May 23, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 3, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 3, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 27, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 27, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 13, 2022 NONP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 6, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 6, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 6, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 6, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 6, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 6, 2022 COAR
APPLICATION FILING RECEIPT MAILED
Apr 1, 2022 MAFR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 31, 2022 CNSA
ASSIGNED TO EXAMINER
Mar 30, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 28, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 23, 2022 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Mar 10, 2022 SDRC